Voyageur Pharmaceuticals Ltd. Stock OTC Markets
Stocks
VYYRF
CA92918C1014
Pharmaceuticals
OTC Markets Traded|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0960 USD | -4.00% |
|
-2.04% | -26.21% |
| Market Cap | 33.95M 24.19M 21M 19.66M 17.98M 2.3B 34.39M 230M 90.26M 1.15B 90.84M 88.87M 3.83B | P/E 2024 |
-5.24x | P/E 2025 | -7.5x |
|---|---|---|---|---|---|
| Enterprise Value | 33.72M 24.03M 20.85M 19.53M 17.86M 2.29B 34.16M 228M 89.65M 1.14B 90.22M 88.26M 3.81B | EV / Sales 2024 |
-
| EV / Sales 2025 | 2,423,581,172x |
| Free-Float |
93.07% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | -4.00% | ||
| 1 week | -2.04% | ||
| 1 month | -4.00% | ||
| 3 months | +20.00% | ||
| 6 months | -12.73% | ||
| Current year | -26.21% |
| 1 week | 0.1 | 0.1 | |
| 1 month | 0.1 | 0.11 | |
| Current year | 0.01 | 0.2 | |
| 1 year | 0 | 0.2 | |
| 3 years | 0 | 0.25 | |
| 5 years | 0 | 0.25 | |
| 10 years | 0 | 0.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Brent Willis
CEO | Chief Executive Officer | - | 01/07/2019 |
| Director of Finance/CFO | - | 17/08/2022 | |
Iryna Saranchova
CTO | Chief Tech/Sci/R&D Officer | - | 17/09/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Brent Willis
BRD | Director/Board Member | - | 06/12/2017 |
Brad Willis
BRD | Director/Board Member | - | 01/07/2019 |
Eric Pommer
CHM | Chairman | - | 30/04/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -4.00% | -2.04% | - | - | 24.19M | ||
| -0.10% | +3.60% | +85.71% | +162.10% | 1,062B | ||
| -0.12% | +0.52% | +50.23% | +48.87% | 619B | ||
| +0.11% | -2.12% | +23.51% | +63.39% | 431B | ||
| +1.41% | +5.09% | +49.18% | +40.31% | 358B | ||
| +0.87% | +0.02% | +36.08% | +40.92% | 293B | ||
| +0.89% | -4.99% | +9.61% | +10.25% | 247B | ||
| +0.41% | +6.15% | +43.61% | +61.64% | 219B | ||
| +4.30% | -0.55% | -1.31% | -44.15% | 200B | ||
| +1.27% | +2.13% | +20.58% | +64.84% | 162B | ||
| Average | +0.58% | -1.90% | +35.24% | +49.80% | 399.14B | |
| Weighted average by Cap. | +0.65% | -0.83% | +48.85% | +76.26% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | 0.01 0.01 0.01 0.01 0.01 0.79 0.01 0.08 0.03 0.4 0.03 0.03 1.32 |
| Net income | -1.71M -1.22M -1.06M -989K -904K -116M -1.73M -11.57M -4.54M -57.9M -4.57M -4.47M -193M | -3.53M -2.52M -2.18M -2.05M -1.87M -240M -3.58M -23.93M -9.39M -120M -9.45M -9.25M -399M |
| Net Debt | -113K -80.26K -69.65K -65.22K -59.66K -7.65M -114K -763K -299K -3.82M -301K -295K -12.71M | -231K -164K -143K -134K -122K -15.65M -234K -1.56M -613K -7.82M -617K -603K -26.03M |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/08/26 | US$0.0960 | -4.00% | 7,500 |
| 04/08/26 | US$0.1000 | +4.17% | 20,000 |
| 31/07/26 | US$0.0960 | -2.04% | 10,000 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- VM Stock
- VYYRF Stock
Select your edition
All financial news and data tailored to specific country editions
















